THAM L, DRUSANO GL, KHOO AL, LEE MK, LEE KH; Interscience Conference on Antimicrobial Agents and Chemotherapy (43rd: 2003: Chicago, Ill.).
Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother. 2003 Sep 14-17; 43: abstract no. A-25.
National University Hospital, Singapore, Singapore.
BACKGROUND: Extracorporeal albumin dialysis with MARS functions as a new supportive intervention for liver failure patients. MARS removes both water-soluble and albumin bound substances. This study aimed to investigate the pharmacokinetics (PK) and extent of amikacin removal by MARS during acute liver failure. METHODS: 9 patients were given 30-minute infusions of amikacin 500mg while under going MARS dialysis. Serum amikacin concentrations were sampled simultaneously from the in and out ports of the MARS dialyzer at no less than 3 time points throughout the 8 to10 hour dialysis period. 3 patients were re-dosed with 1g of amikacin 3.5 hours into MARS. Residual amikacin renal clearance was expressed as a function of creatinine clearance, fixed at 5ml/min (CLr = a + b*CLcr). All data were modeled via a population PK analysis employing BigNPAG (Non-Parametric Adaptive Grid) with adaptive g to determine the population mean parameter vector values. RESULTS: Table 1 [table: see text] illustrates the population's mean parameter vector values for amikacin. The mean extraction ratio was 0.427 +/- 0.143. CONCLUSION: This is the first population PK study based on the MARS dialysis model. Amikacin exhibited substantial clearance during MARS dialysis. Individualized PK dosing using the mean PK parameters derived would ensure achievement of target Cmax/MIC ratio.
Publication Types:
Keywords:
- Albumins
- Amikacin
- Antidotes
- Dialysis
- Dialysis Solutions
- Fluid Therapy
- Gastrointestinal Agents
- Humans
- Liver Failure
- Liver Failure, Acute
- Mars
- Renal Dialysis
- pharmacokinetics
Other ID:
UI: 102266037
From Meeting Abstracts